Michigan MD Faces DEA Ban for Sketchy Prescribing and Patient Coaching
Published Date: 5/7/2025
Notice
Summary
Dr. Mohan Kaza from Michigan had his DEA license suspended and is now losing it for giving out strong prescription drugs without proper exams or checks. He also coached undercover agents to lie and charged extra fees for higher doses. This decision protects public safety by stopping unsafe prescribing practices immediately.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Physician
DEA Certificate of Registration No. FK8011063 issued to Mohan Kaza, M.D., is revoked, removing his DEA registration and associated authority to prescribe or dispense controlled substances under that registration. The revocation is ordered by the DEA and takes effect June 6, 2025.
Pending Michigan Registration Applications Denied
DEA denied any pending applications of Mohan Kaza, M.D., to renew or modify his registration and denied any other pending applications for additional registration in Michigan. That denial is part of the same Order effective June 6, 2025.
Order Stops Unsafe Prescribing Practices
The DEA found that between January 17, 2024 and April 17, 2024 the physician issued seven controlled-substance prescriptions to two undercover individuals without proper assessments, coached them to provide false medical histories, dispensed at least one tablet without a prescription, and charged higher cash fees for higher dosages. The Order revokes the registration to protect public safety and stop those unsafe prescribing practices immediately.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-07935, Edmund Ayoub Jr., M.D.; Decision and Order
Dr. Edmund Ayoub Jr. from California lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Next: 2025-07939, Change in Control: Mexico Pacific Limited LLC
Mexico Pacific Limited LLC is changing who owns the company’s upstream operations. The Department of Energy got the official notice in March 2025, so this change is now on the record. This update affects anyone tracking energy ownership and could impact future natural gas activities.